Slide 1: MariTide Update
MariTide Update June 23, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outco
Slide 3: MariTide: A Unique, Differentiated and Competitive Profile
MariTide: A Unique, Differentiated and Competitive Profile • First obesity treatment with monthly or less frequent dosing • Strong efficacy with up to ~20% weight loss without a plateau at 52 weeks • Meaningful improvements in cardiometabolic parameters including HbA1c, systolic blood pressure, and
Slide 4: Today's Topics
MariTide Update Today’s Topics 52-Week Data from Part 1 of Phase 1 Pharmacokinetic 1 the Phase 2 study 2 Low Dose Initiation Study Phase 3 Chronic Weight 3 Management Study Design 4 MariTide Data Generation 4 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains
Slide 5: MariTide: First Monthly or Less Frequent Treatment for Obesity and Type 2 Diabetes
MariTide: First Monthly or Less Frequent Treatment for Obesity and Type 2 Diabetes Monoclonal (anti-GIPR) antibody Two GLP-1R analog peptides backbone with long half-life enables positioned for optimal efficacy monthly or less frequent dosing MariTide’s simple and convenient dosing can potentially i
Slide 6: Overview of MariTide Phase 2 Study (Part 1)
Overview of MariTide Phase 2 Study (Part 1) Obesity or Overweight WITHOUT Type 2 Diabetes (n=465) • 52 week duration 140 mg monthly • 2 cohorts 280 mg monthly 1. Adults living with obesity or overweight 420 mg monthly WITHOUT Type 2 diabetes 420 mg every other month 2. Adults living with obesity or
Slide 7: Consistent Weight Loss Across All Target Dose Arms Without Type 2 Diabetes
MariTide Demonstrated Consistent Weight Loss Across All Target Dose Arms in Adults With Obesity WITHOUT Type 2 Diabetes 5 Overall mean baseline weight = 107.4 kg Percent change in body weight • MariTide demonstrated up to 0 ~ 20% average weight loss -2.6 without a plateau at 52 weeks -5 • Confirmed
Slide 8: Dose Escalation and Every Other Month Dosing Efficacy Comparable to 420 mg Monthly
Dose Escalation and Every Other Month Dosing of MariTide Demonstrated Efficacy Comparable to 420 mg Monthly Dosing 5 Overall mean baseline weight = 107.4 kg Percent change in body weight • Dose escalation resulted in 0 similar magnitude of -2.6 weight loss compared to -5 no dose escalation -10 • Eve
Slide 9: Up to ~17% Average Weight Loss at 52 Weeks With Type 2 Diabetes
MariTide Demonstrated an Impressive Up to ~17% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in Adults With Obesity WITH Type 2 Diabetes 0 • Substantial and statistically Percent Change in Body Weight -2 -1.4 significant weight loss in all estimated mean (95% CI) treatment arms -4 -6
Slide 10: Cardiometabolic Improvements in Adults With Obesity WITH Type 2 Diabetes
MariTide Demonstrated Significant and Clinically Meaningful Improvements in Cardiometabolic Parameters in Adults With Obesity WITH Type 2 Diabetes Overall mean baseline HbA1c = 7.9% 1 CHANGE FROM Change in hemoglobin A1c (%) SELECT CHANGE FROM BASELINE TO W52 CARDIOMETABOLIC BASELINE TO W52 FOR MARI
Slide 11: Cardiometabolic Improvements in Adults With Obesity WITHOUT Type 2 Diabetes
MariTide Demonstrated Significant and Clinically Meaningful Improvements in Cardiometabolic Parameters in Adults With Obesity WITHOUT Type 2 Diabetes Overall mean baseline HbA1c = 5.5% 0.4 CHANGE FROM Change in hemoglobin A1c (%) SELECT CHANGE FROM BASELINE TO W52 FOR 0.2 CARDIOMETABOLIC BASELINE TO
Slide 12: Findings From Multiple Studies Optimize MariTide's Tolerability Profile in Phase 3
Findings From Multiple Studies Provide the Insights to Optimize MariTide’s Tolerability Profile in Phase 3 • Overall safety consistent with GLP-1 class • Efficacy is durable, while gastrointestinal adverse events are short lived and predominantly associated with initial doses of MariTide • MariTide
Slide 13: MariTide Well Tolerated at Target Doses in Phase 2
In Part 1 of the Phase 2 Study, MariTide was Well Tolerated at Target Doses No-Step (No Dose Escalation) Vomiting Incidence rate (%) 100 90 80 70 60 420 mg Q4W 50 40 30 20 10 0 12 4 8 12 16 20 24 28 32 36 40 44 48 52 420 420 420 420 420 420 420 420 420 420 420 420 420 mg mg mg mg mg mg mg mg mg mg m
Slide 14: Tolerability Improved at Initiation With One-Step Dose Escalation
MariTide Tolerability was Improved at Initiation With One-Step Dose Escalation No-Step (No Dose Escalation) One-Step Dose Escalation Vomiting Incidence rate (%) Vomiting Incidence rate (%) 100 100 90 90 80 80 70 60 420 mg Q4W 70 60 420 mg Q4W (4W-Dose Escalation) 50 50 40 40 30 30 20 20 10 10 0 0 12
Slide 15: Two-Step Dose Escalation Evaluated Through Phase 1 Low Dose Initiation Study
Two-Step Dose Escalation was Evaluated Through a Phase 1 Low Dose Initiation Study DAY 1 RANDOMIZATION 1:1:1 N= 121 DAY 15 DAY 29 DAY 43 DAY 99 350 mg g m 0 7 1 21 mg 70 mg END Continued GROUP 2 35 mg 70 mg 350 mg OF Follow-up STUDY 3 70 mg 70 mg 350 mg Phase 1 Center Phase 1 Center Phase 1 Center P
Slide 16: Two-Step Dose Escalation Improved Incident GI Adverse Events
Two-Step Dose Escalation Improved Incident GI Adverse Events and Reinforced That Events Were Short Lived No event Mild Moderate Severe Group 3: one-step dose escalation Group 2: two-step dose escalation Group 1: two-step dose escalation 70/70/350 mg 35/70/350 mg 21/70/350 mg (one row per individual)
Slide 17: Meaningful Improvements in Tolerability With Each Additional Dose Escalation Step
Meaningful Improvements in Tolerability Observed With Each Additional Dose Escalation Step No-Step One-Step Dose Escalation Two-Step Dose Escalation 100 90 80 Vomiting incidence % 70 60 50 40 30 Use three-step dose 20 escalation to further 10 improve tolerability in Phase 3 0 420 mg 280 mg 140 mg 70
Slide 18: Dose Escalation in Low Dose Initiation Study Delivered Meaningful Weight Loss
Dose Escalation in the MariTide Phase 1 Low Dose Initiation Study Delivered Meaningful Weight Loss Day 0 5 10 15 20 25 30 35 40 0 % Change from baseline -2.5 in body weight -5 -5.5 -6.2 -7.0 -7.5 Mean baseline weight = 100.6 kg -10 MariTide administration: Group 1: 21/70/350 mg, n=41 Group 2: 35/70/
Slide 19: Three-Step Dose Escalation Will be Used to Further Improve Tolerability in Phase 3
Three-Step Dose Escalation Will be Used to Further Improve MariTide’s Tolerability Profile in Phase 3 Dose Escalation No-Step One-Step Two-Step Three-Step Study Phase 2 Phase 2 Phase 1 LDI Phase 3 Duration – 2-4 weeks 4 weeks 8 weeks Nausea Expect Further High Lower Even Lower Vomiting Improvement i
Slide 20: MariTide Phase 3 Chronic Weight Management Study Designs
MariTide Phase 3 Chronic Weight Management Study Designs WITH and WITHOUT Type 2 Diabetes Treatment period Day 1 W2 W4 W8 W 72 21 mg 35 mg 70 mg Target Dose: 350 mg MariTide monthly 21 mg 35 mg 70 mg Target Dose: 210 mg MariTide monthly 21 mg 35 mg 70 mg Target dose: 140 mg MariTide monthly 8 week t
Slide 21: MariTide Data Generation
MariTide Data Generation Additional Phase 3 study initiations Studies in Progress Atherosclerotic Cardiovascular Phase 3 chronic weight Disease Outcomes management study in patients WITHOUT Type 2 diabetes Heart failure Phase 3 chronic weight management study in patients WITH Type 2 diabetes Obstruc
Slide 22: Key Takeaways
Key Takeaways • First obesity treatment with monthly or less frequent dosing • Strong efficacy with up to ~20% weight loss without a plateau at 52 weeks • Meaningful improvements in cardiometabolic parameters including HbA1c, systolic blood pressure, and high-sensitivity C-reactive protein • Tolerab
Slide 23: Questions?
QUESTIONS? _ {ye Gap GD 430 . GD 4 p> GED © GED GED @ Dp O@GD =, aD @u :
Slide 24: Observed Pharmacokinetics
Observed Pharmacokinetics Day 1 (MariTide 21, 35, or 70 mg SC) Mean MariTide Plasma Concentration (µg/mL) Group tmax (day) Cmax (µg/mL) AUC0-14 (day × µg/mL) 100.0 Group 1: 21/70/350 mg 9.0 (2.0-14.0) 1.08 (52.8%) 11.3 (59.0%) N = 41 Group 2: 35/70/350 mg 7.0 (3.0-14.1) 1.95 (47.9%) 20.6 (50.7%) N =
Slide 25: About Phase 2 Efficacy Estimand and Treatment Policy Estimand
About Phase 2 Efficacy Estimand and Treatment Policy Estimand (Intent-to-Treat Analysis) • The efficacy estimand represents the efficacy as if treated participants had adhered to MariTide for the entire 52-week study period. The efficacy estimand includes endpoint data so long as study drug is taken